93861-57-5

Basic information

• Product Name: glycoursodeoxycholic acid
• CAS NO: 93861-57-5
• Molecular Weight: 449.631
• Mol File: 93861-57-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: glycoursodeoxycholic acid(CAS DataBase Reference)
• NIST Chemistry Reference: glycoursodeoxycholic acid(93861-57-5)
• EPA Substance Registry System: glycoursodeoxycholic acid(93861-57-5)

Safety Data

• Hazardous Substances Data: 93861-57-5(Hazardous Substances Data)

Upstream product

• 128-13-2 ursodeoxycholic acid 
• 178437-09-7 3α,7β-dihydroxy-5β-cholan-24-oic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 56-40-6 glycine 
• 174069-12-6 3α,7α-dihydroxy-5β-cholan-24-oic acid 2,5-dioxopyrrolidin-1-yl ester 
• 474-25-9 chenodeoxycholic acid 
• 115488-03-4 glycine ursodeoxycholic acid ethyl ester 

Relevant articles and documents

Continuous flow synthesis and scale-up of glycine- and taurine-conjugated bile salts

A multi-gram scale protocol for the N-acyl amidation of bile acids with glycine and taurine has been successfully developed under continuous flow processing conditions. Selecting ursodeoxycholic acid (UDCA) as the model compound and N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) as the condensing agent, a modular mesoreactor assisted flow set-up was employed to significantly speed up the optimization of the reaction conditions and the flow scale-up synthesis. The results in terms of yield, in line purification, analysis, and implemented flow set-up for the reaction optimization and large scale production are reported and discussed.

Synthesis, anticancer activities, antimicrobial activities and bioavailability of berberine-bile acid analogues

Fifteen berberine-bile acid analogues were synthesized. Anticancer activities of these analogues compared with berberine (BBR) were evaluated in vitro; among the analogues, A4, B4, and B5 had higher cytotoxicity than that of BBR. Most of the analogues showed higher antimicrobial activity against Staphylococcus aureus ATCC 25923 and Staphylococcus albus ATCC 8799 than that of BBR, but Bacillus subtilis AS 1.398 and Escherichia coli ATCC 31343 were not sensitive to all of the analogues. A4 and B4 were stable in the serum stability assay. B4 showed promising oral bioavailability in mice.

An improved procedure for the synthesis of glycine and taurine conjugates of bile acids

Glycine and taurine conjugates of 5β cholanic acids have been synthesized using improved procedures based on the peptide coupling reagent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. The conjugates are obtained in chromatographically pure form in yields higher than 90%. The use of this procedure in the large scale preparation of choly[1,2 13C2]glycine is described.